Skip to main content

sevelamer carbonate

Generic: SEVELAMER CARBONATE·Brand: RENVELA, SEVELAMER CARBONATE

sevelamer carbonate: sourced relationships with 2 companies · 2 clinical trials tracked · 3 FDA decisions.

sevelamer carbonate evidence translation

What we can confirm

3 FDA records · 2 tracked trials

What it means

More than one company relationship is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

What is verified about sevelamer carbonate, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Dated Pipeline Records (3)
CompanyDated record stage
DR REDDYS LABORATORIES LTD (RDY)
Reported 2017-09-29 · Current development: unknownSource
Approved
Sanofi (SNY)
Reported 2007-10-19 · Current development: unknownSource
Approved
Sanofi (SNY)
Reported 2007-10-19 · Current development: unknownSource
Approved
Clinical Trial Registry Records (2)

A Post-Marketing Open-Label, 5 Period Crossover, Drug-Drug Interaction Study of Orally Adminstered TPOXX When Co-administered With 4 Different Phosphate Binders in Healthy Subjects

NCT04485039Registry updated 2026-09-11·Phase 4·SIGA
Completed

Primary endpoint: AUC0-inf

InterventionalRandomizedopen44 enrolledStarted 2022-06Completion 2023-041 site · United StatesSIGA Technologies

Randomized Placebo Controlled Double-blind Trial in CKD Patients Not on Dialysis to Evaluate the Effect of Sevelamer Carbonate in the Control of FGF-23 Serum Levels and Its Consequences in the Evolution of PTH, Calcitriol and Mineral Metabolism Parameters Levels

NCT01220843Registry updated 2025-09-19·Phase 3
Completed

Primary endpoint: Measurement of the serum levels of C terminal segment of fibroblast growth factor 23 (FGF23) and evaluation of sevelamer carbonate effect on this levels in comparison with placebo

InterventionalRandomizedtriple98 enrolledStarted 2010-10Completion 2013-0415 sites · FranceCentre Hospitalier Universitaire, Amiens
FDA Decisions3 records
Approval(RDY)FDA ↗
ANDA210464UNKNOWNStandardOralFor Suspension
Approval(RDY)FDA ↗
ANDA206094UNKNOWNStandardOralTablet
Approval1 INDICATIONS AND USAGE Sevelamer carbonate is indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis. Sevelamer carbonate is a phosphate binder indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis. ( 1 )(SNY)FDA ↗
NDA022127Type 3 - New Dosage FormStandardOralTablet

Frequently asked questions

Which companies have sourced relationships with sevelamer carbonate?

sevelamer carbonate has dated SEC/FDA relationship records for DR REDDYS LABORATORIES LTD, Sanofi.

How many clinical trials involve sevelamer carbonate?

BioSniper tracks 2 clinical trials involving sevelamer carbonate.

What is sevelamer carbonate's latest FDA decision?

The most recent tracked FDA decision for sevelamer carbonate is Approval, dated October 25, 2018.